WEGOVY® FLEXTOUCH® 0.25 mg is a once-weekly injectable pen containing semaglutide, prescribed for adults with obesity or overweight (with at least one weight-related condition) as part of a comprehensive program including diet and exercise. The 0.25 mg dose serves as the initiation phase, helping the body adapt to therapy before escalating to higher maintenance doses.

Key Benefits
• Starter dose designed to improve tolerability and acclimation to treatment
• Supports weight reduction by decreasing appetite and calorie intake
• Flexible once-weekly dosing via a pre-filled injection pen
• Ideal for use in comprehensive weight-management programmes
• Facilitates transition into higher therapeutic doses when appropriate

How It Works
Semaglutide, the active ingredient in WEGOVY®, is a GLP-1 receptor agonist that mimics the body’s natural incretin hormones. It enhances insulin secretion in response to elevated glucose, reduces glucagon release, slows gastric emptying, and decreases hunger signals. Collectively, these processes help reduce body weight, improve metabolic markers, and assist long-term weight maintenance.

Ideal Candidates
• Adults with obesity (BMI ≥ 30 kg/m²)
• Adults with overweight (BMI ≥ 27 kg/m²) plus at least one weight-related comorbidity (e.g., type 2 diabetes, hypertension, dyslipidaemia)
• Patients commencing pharmacotherapy for weight management, starting at the initiation dose
• Individuals able to commit to lifestyle modifications (diet + exercise) alongside medication

Administration
Administered subcutaneously once a week using the pre-filled FLEXTOUCH® pen, into the abdomen, thigh, or upper arm. This 0.25 mg dose is typically used during the first four weeks of therapy. After this initiation phase, the dose is escalated at four-week intervals based on patient response and tolerability.

Possible Side Effects
Frequently experienced side effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, and decreased appetite, particularly during dose escalation. These often lessen over time. Less common but serious risks may include pancreatitis, gallbladder disease, acute kidney injury, or thyroid C-cell tumours. Patients should be monitored and assessed by a qualified healthcare provider throughout treatment.